Compare Lululemon Athletica Inc (LULU) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Lululemon Athletica Inc vs ResMed Inc. — how do they compare? Lululemon Athletica Inc trades at $113.65 (market cap $13.24B), while ResMed Inc. trades at $192.97 (market cap $28.40B). The key difference: ResMed Inc. is far larger — about 2.1× Lululemon Athletica Inc's market cap, and ResMed Inc. pays a 1.23% dividend while Lululemon Athletica Inc pays none. Which is the better fit depends on your goals.
| LULU | RMD | |
|---|---|---|
Market Cap | $13.24B | $28.40B |
Sector | Consumer Cyclical | Health |
52-Week High | $224.03 | $293.73 |
52-Week Low | $105.43 | $182.82 |
Enterprise Value | $13.87B | $27.58B |
Dividend Yield | — | 1.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Lululemon trades at $116.63, up 0.26% today, amid bearish technical signals but strong fundamentals. The stock shows consistent earnings beats, with Q1 2026 EPS of $1.69 exceeding the $1.67 estimate. Revenue grew to $10.59B in 2025, with a net income margin of 17.13%. Recent news includes a $30M investment in nylon recycling startup Syntetica and resolution of a proxy battle with founder Chip Wilson, boosting shareholder confidence.
The outlook is mixed: valuation metrics like a P/E of 9.45 and EV/EBITDA of 5.41 suggest potential upside to the $129.29 consensus target, but technical bearishness and competitive pressures pose risks. Investors may find value in robust profitability and strategic initiatives, though macroeconomic headwinds and brand controversies require monitoring.
ResMed (RMD) trades at $195.8, down 1.6% on the day, with a bearish technical signal but strong fundamentals. Recent quarterly earnings have consistently beaten estimates, with Q1 2026 EPS of $2.86 exceeding the $2.80 forecast. The company sold its MatrixCare business for $490 million in July 2026 to sharpen focus on connected care, signaling strategic refinement. Revenue growth remains robust, climbing to $5.15 billion in 2025, with net income margins expanding to 27.44%.
The outlook is supported by solid earnings momentum and a consensus price target of $245.88, implying 25.6% upside. Risks include competitive pressures in medical equipment and reliance on sleep apnea market growth. Analyst sentiment is mixed with 40% buy ratings, but institutional selling by Baader Bank in Q1 2026 warrants monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Lululemon Athletica Inc
Lululemon Athletica Inc. designs, distributes, and markets athletic apparel, footwear, and accessories for women, men, and girls. Lululemon offers pants, shorts, tops, and jackets for both leisure and athletic activities such as yoga and running. The company also sells fitness accessories, such as bags, yoga mats, and equipment. Lululemon sells its products through more than 600 company-owned stores in 18 countries, e-commerce, outlets, and wholesale accounts. The company was founded in 1998 and is based in Vancouver, Canada.
Read more on LULU →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
